Novartis eye unit subpoenaed in U.S. probe

Novartis ($NVS) has disclosed a U.S. government probe into alleged healthcare fraud at its newly acquired eyecare unit Alcon, Reuters reports. The company received a subpoena from HHS, requesting documents involving sales of four drugs, including Vigamox and Nevanac, and surgical equipment. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.